

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Amended) An antagonist that specifically binds to a denatured collagen or collagens but binds to the native triple helical form of each of said collagens with substantially reduced affinity and wherein said antagonist inhibits angiogenesis, wherein the antagonist is an antibody.
2. (Original) The antagonist of claim 1 wherein said reduced affinity is about 3 fold lower than that for said denatured collagen.
3. (Original) The antagonist of claim 1 wherein said reduced affinity is about 5 fold lower than that for said denatured collagen.
4. (Original) The antagonist of claim 1 wherein said reduced affinity is about 10 fold lower than that for said denatured collagen.
5. (Canceled)
6. (Previously Presented) The antagonist of claim 1 wherein said denatured collagen is denatured collagen type-I.

Claims 7 - 9 (Canceled)

10. (Original) The antagonist of claim 6 wherein said antagonist is a monoclonal antibody.
11. (Canceled)
12. (Original) The antagonist of claim 6 wherein the antagonist is a polyclonal antibody.

Claims 13 - 15 (Canceled)

16. (Original) The antagonist of claim 6 wherein the antagonist is a humanized or chemically modified monoclonal antibody.

17. (Original) The antagonist of claim 6 wherein the antagonist is a fragment of a monoclonal antibody.

18. (Original) The antagonist of claim 6 wherein the antagonist is conjugated to cytotoxic or cytostatic agents.

19. (Canceled)

20. (Withdrawn) The method of claim 60 wherein said antagonist is administered intravenously, transdermally, intrasynovially, intramuscularly, intratumorally, intraocularly, intranasally, intrathecally, topically or orally.

21. (Withdrawn) The method of claim 60 wherein said antagonist is administered in conjunction with chemotherapy.

22. (Withdrawn) The method of claim 60 wherein said antagonist is administered in conjunction with radiation.

23. (Withdrawn) The method of claim 60 wherein the tissue is inflamed and angiogenesis is occurring.

24. (Withdrawn) The method of claim 23 wherein the tissue is present in a mammal.

25. (Withdrawn) The method of claim 24 wherein the tissue is arthritic, ocular, retinal or a hemangioma.

26. (Canceled)

27. (Withdrawn) The method of claim 61 wherein said antagonist is administered intravenously, transdermally, intrasynovially, intramuscularly, intratumorally, intraocularly, intranasally, topically or orally.

28. (Withdrawn) The method of claim 61 wherein said antagonist is administered in conjunction with chemotherapy.
29. (Withdrawn) The method of claim 61 wherein said antagonist is administered in conjunction with radiation.
30. (Withdrawn) The method of claim 61 wherein the tumor or metastasis is a melanoma, carcinoma, sarcoma, fibrosarcoma, glioma or astrocytoma.
31. (Canceled)
32. (Withdrawn) The method of claim 62 wherein said antagonist is administered intravenously, transdermally, intrasynovially, intramuscularly, intratumorally, intraocularly, intranasally, intrathecally, topically or orally.
33. (Withdrawn) The method of claim 62 wherein administering the antagonist is in conjunction with chemotherapy.
34. (Withdrawn) The method of claim 62 wherein administering the antagonist is in conjunction with radiation.
35. (Canceled)
36. (Withdrawn) The method of claim 63 wherein said tissue is *ex vivo*.
37. (Withdrawn) The method of claim 63 wherein said tissue is *in vivo* and said antagonist is administered intravenously, transdermally, intrasynovially, intramuscularly, intratumorally, intraocularly, intranasally, intrathecally, topically or orally.
38. (Withdrawn) The method of claim 63 wherein said antagonist is conjugated to a fluorochrome, radioactive tag, paramagnetic heavy metal, diagnostic dye or enzyme.
39. (Canceled)
40. (Withdrawn) The method of claim 64 wherein said tissue is *ex vivo*.

41. (Withdrawn) The method of claim 64 wherein said tissue is *in vivo* and said antagonist is administered intravenously, transdermally, intrasynovially, intramuscularly, intratumorally, intraocularly, intranasally, intrathecally, topically or orally.

42. (Withdrawn) The method of claim 64 wherein said antagonist is conjugated to a fluorochrome, radioactive tag, paramagnetic heavy metal or diagnostic dye.

43. (Withdrawn) A method for screening for denatured collagen antagonists comprising:

- a) providing a putative antagonist;
- b) measuring said putative antagonist's first affinity for a denatured collagen selected from the group consisting of collagens types I, II, III, IV and V;
- c) measuring said putative antagonist's second affinity for a native collagen selected from the group consisting of collagens types I, II, III, IV and V, wherein said native collagen selected is the native form of the denatured collagen selected; and
- d) selecting said putative antagonist as a denatured collagen antagonist if said second affinity is substantially less than said first affinity.

44. (Withdrawn) The method of claim 43 wherein said putative antagonist is a non-peptidic compounds.

45. (Withdrawn) The method of claim 44 wherein said non-peptidic compound is a small organic compound.

46. (Withdrawn) The method of claim 44 wherein said non-peptidic compound is an oligonucleotide.

47. (Withdrawn) The method of claim 43 wherein said putative antagonist is a polypeptide, a linear peptide or a cyclic peptide.

48. (Withdrawn) The method of claim 43 wherein said putative antagonist is an antibody.

49. (Withdrawn) The method of claim 48 wherein said antibody is monoclonal.

50. (Withdrawn) The method of claim 48 wherein said antibody is polyclonal.

51. (Withdrawn) The method of claim 43 wherein said first and said second affinities are measured by an enzyme linked immunosorbent assay.

52. (Withdrawn) The method of claim 43 wherein second affinity is about 3 times less than said first affinity.

53. (Withdrawn) The method of claim 43 wherein said second affinity is about 5 times less than said first affinity.

54. (Withdrawn) The method of claim 43 wherein said second affinity is about 10 times less than said first affinity.

55. (Withdrawn) A method for screening for denatured collagen antagonists comprising selecting an antagonist for the ability to compete with an antagonist of claim 11 for binding an epitope in denatured collagen.

56. (Withdrawn) A peptide comprising a sequence encoding an epitope recognized by the antagonist of claim 1.

57. (Withdrawn) The peptide of claim 56 wherein said antagonist is a monoclonal antibody.

58. (Withdrawn) The peptide of claim 57 wherein said antibody is HU177, HUIV26 or XL313.

59. (Withdrawn) The peptide of claim 58 wherein said peptide is SEQ ID NO: 12.

60. (Withdrawn) A method of inhibiting angiogenesis in a tissue comprising administering the antagonist of claim 1.

61. (Withdrawn) A method of inhibiting tumor growth or metastasis in a tissue comprising administering the antagonist of claim 1.

62. (Withdrawn) A method of inhibiting psoriasis, macular degeneration, or restenosis in a tissue comprising administering the antagonist of claim 1.

63. (Withdrawn) A method of detecting angiogenesis in a tissue comprising contacting the antagonist of claim 1 with said tissue.

64. (Withdrawn) A method of detecting tumors or tumor invasion in a tissue comprising administering the antagonist of claim 1.

65. (Previously Presented) The antagonist of claim 10 or claim 69 wherein said monoclonal antibody is a monoclonal antibody having the binding specificity of monoclonal antibody HUI77.

66. (Previously Presented) The antagonist of claim 10 or claim 69 wherein said monoclonal antibody is a monoclonal antibody having the binding specificity of monoclonal antibody HUIV26.

67. (Previously Presented) The antagonist of claim 10 or claim 69 wherein said monoclonal antibody is a monoclonal antibody having the binding specificity of monoclonal antibody XL313.

68. (Previously Presented) The antagonist of claim 1 wherein said denatured collagen is selected from a group consisting of denatured collagen type-I, denatured collagen type-II, denatured collagen type-III, denatured collagen IV, and denatured collagen type-V.

69. (Previously Presented) The antagonist of claim 68 wherein said antagonist is a monoclonal antibody.

70. (Previously Presented) The antagonist of claim 68 wherein the antagonist is a polyclonal antibody.

71. (Previously Presented) The antagonist of claim 68 wherein the antagonist is a humanized or chemically modified monoclonal antibody.

72. (Previously Presented) The antagonist of claim 68 wherein the antagonist is a fragment of a monoclonal antibody.

73. (Previously Presented) The antagonist of claim 68 wherein the antagonist is conjugated to cytotoxic or cytostatic agents.

74. (New) The antagonist of claim 1 wherein said antibody binds to a cryptic epitope that is exposed in the denatured form of collagen and wherein said epitope is involved in endothelial cell adhesion to denatured collagen.

75. (New) The antagonist of claim 1 wherein said antibody binds to a cryptic epitope that is exposed in the denatured form of collagen and wherein said epitope is involved in cellular migration on denatured collagen.

76. (New) An antagonist that specifically binds to a denatured collagen or collagens but binds to the native triple helical form of each of said collagens with substantially reduced affinity, wherein said antagonist is an antibody that inhibits fibroblast growth factor (bFGF)-induced angiogenesis.

77. (New) The antagonist of claim 1, wherein the angiogenesis is a tumor-induced angiogenesis.

78. (New) An antagonist that specifically binds to a denatured collagen or collagens but binds to the native triple helical form of each of said collagens with

substantially reduced affinity, wherein said antagonist is an antibody that inhibits angiogenesis-mediated tumor growth.

79. (New) The antagonist of claim 78 wherein the antibody inhibits melanoma tumor growth.

80. (New) The antagonist of claim 78 wherein the antibody inhibits Lewis lung carcinoma tumor growth.

81. (New) The antagonist of claim 1 wherein said antibody binds to a cryptic epitope that is exposed in denatured collagen and wherein said epitope is involved in endothelial cell survival.

82. (New) The antagonist of claim 1 wherein said antibody binds to a cryptic epitope that is exposed in denatured collagen and wherein said epitope is located in a helical region of collagen.

83. (New) The antagonist of claim 1 wherein said antibody binds to a portion of a collagen sequence that lies outside of an arginine-glycine-aspartic acid (RGD)-containing region.